Hedge Fund Trade Of The Week (ENZN)

Anthony Scaramucci was on CNBC and just mentioned Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) as a potential double from these levels.

Scaramucci said the company has royalty streams from two drugs, and has $5 per share in cash, and is extremely cheap at these levels.

Scaramucci said the company could sell its royalty streams in the drugs it owns, or potentially sell the whole company. Seth Klarman, who is a noted value investor, owns 17% of the company.

Scaramucci believes the company could be worth $20-$25 per share.

Get free trades at tradeMONSTER!